Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016.info:eu-repo/semantics/publishedVersio
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018...
Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the develop...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol h...
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016.in...
A correction has been published: European Heart Journal, Volume 39, Issue 22, 7 June 2018, Pages 210...
This ESC/EAS Task Force consensus document provides clinicians with practical guidance for the use o...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the degradation of low-density lipopro...
This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for prop...
Summary. Dyslipidemia is one of the predominant causes of atherosclerosis and cardiovascular disease...
The treatment of hypercholesterolemia entered in a new phase of development with the introduction of...
The severe hypercholesterolaemia can be recognised when low density lipoprotein cholesterol (LDL-C...
Sanjiv Gupta Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medic...
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appear to represent an importan...
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018...
Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the develop...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol h...
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016.in...
A correction has been published: European Heart Journal, Volume 39, Issue 22, 7 June 2018, Pages 210...
This ESC/EAS Task Force consensus document provides clinicians with practical guidance for the use o...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the degradation of low-density lipopro...
This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for prop...
Summary. Dyslipidemia is one of the predominant causes of atherosclerosis and cardiovascular disease...
The treatment of hypercholesterolemia entered in a new phase of development with the introduction of...
The severe hypercholesterolaemia can be recognised when low density lipoprotein cholesterol (LDL-C...
Sanjiv Gupta Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medic...
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appear to represent an importan...
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018...
Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the develop...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol h...